MiniMed Group has filed for a proposed IPO on Nasdaq. The company develops, manufactures, and markets a full range of medical technology solutions for diabetes management. It has been in business for over 40 years and claims to be the only company offering a fully integrated diabetes management system.
MiniMed says its system provides a seamless experience for users, combining privacy, reliability, and a leading dosing algorithm that improves blood sugar control. The company highlights two main benefits: better health outcomes by helping people manage glucose levels effectively, and reducing the daily burden of diabetes for patients, families, and healthcare providers.
Goldman Sachs, BofA Securities, Citigroup, and Morgan Stanley are set to lead the IPO.
